Israel and UAE team up on stem cell therapy research for COVID-19 – UPI News

David Adom wears protective clothing while working in a coronavirus drive through tent in Jerusalem. On Monday, Israel and United Arab Emirates stem cell companies announced collaboration on research on COVID-19 treatments. Photo by Debbie Hill/UPI | License Photo

Aug. 17 (UPI) -- Israel and United Arab Emirates stem cell therapy companies signed an agreement Monday to collaborate on researching potential treatment for COVID-19.

The accord between Israel's Pluristem Therapeutics and UAE's Abu Dhabi Stem Cells Center aims to capitalize on each company's expertise to develop therapies and regenerative medicines for the treatment of severe diseases including COVID-19, according to a joint statement.

Both companies have been treating COVID-19 patients with stem cells.

Pluristem has been treating COVID-19 patients with a placenta-based stem cell therapy. The U.S. Food and Drug Administration cleared the Israel stem cell therapy company in May for a Phase II study of the treatment for severe COVID-19 cases. Preliminary results released in May from compassionate-use programs in Israel and the United States were promising, showing that 75 percent of participants no longer needed mechanical ventilation within 28 days.

The Abu Dhabi Stem Cells Center has started a therapy that returns blood-based stem cells back into the patient's lungs as a fine mist through a nebulizer.

"We are extremely proud to partner with our colleagues at the ADSCC by sharing knowledge and expertise that we believe will advance healthcare within and across our borders," Pluristem CEO and President Yaky Yanay said in the statement.

The ADSCC's General Manager Dr. Yendry Ventura also commented on the deal in the statement.

"Pluristem is a major player in the cell therapy field with years of experience, a unique platform and robust clinical pipeline," Ventura said. "We are excited to join forces and to promote the research and development of cell therapies for the best of the patients and the human society as a whole."

The deal is the second cross-border agreement since President Donald Trump brokered a deal to normalize ties between Israel and the UAE. It follows a cross-border deal on Sunday between UAE-based APEX National Investment and Israel's TeraGroup to conduct research on the coronavirus.

World News // 21 minutes ago

South Korea official proposes changes to U.S. working group

Aug. 18 (UPI) -- South Korea's newly appointed unification chief proposed "readjustments" to a bilateral working-level group with the United States, during a meeting with the top U.S. envoy in Seoul.

World News // 3 hours ago

6.6-magnitude earthquake strikes Philippines; 1 dead

Aug. 18 (UPI) -- A 6.6-magnitude earthquake struck central Philippines Tuesday, killing at least one person, officials said.

World News // 14 hours ago

Toronto police agree to $12.5M settlement for mass arrests at G-20

Aug. 17 (UPI) -- Ten years after mass-arrests in Toronto at the 2010 G-20 economic summit, the Toronto Police Services Board will pay a $12.5 million settlement to members of a class-action lawsuit of 1,100 people who were detained.

World News // 19 hours ago

Spanish Royal Household confirms former king Juan Carlos I is in UAE

Aug. 17 (UPI) -- Spain's Royal Household confirmed Monday that emeritus king, Juan Carlos I, is in United Arab Emirates after uncertainty since he went into exile two weeks ago amid financial scandals.

World News // 19 hours ago

China has new weapon to target airfields, state media says

Aug. 17 (UPI) -- Beijing's military has developed a hybrid weapon capable of destroying an entire airfield with one hit, according to Chinese state media on Monday.

World News // 20 hours ago

South Korea police to handle spy cases, report says

Aug. 17 (UPI) -- Seoul's National Police Agency will take control over all investigations into anti-state espionage previously conducted by the National Intelligence Service.

World News // 22 hours ago

BTS music label worth $2.5B ahead of IPO, report says

Aug. 17 (UPI) -- The South Korean label that manages boy band BTS is expected to make an initial public offering after passing a preliminary screening, according to a South Korean press report.

World News // 22 hours ago

Ryanair cuts capacity for next 2 months due to restrictions

Aug. 17 (UPI) -- Irish carrier Ryanair announced Monday it will reduce flight capacity by 20% in September and October, due to European travel restrictions.

World News // 23 hours ago

North Korea quiet as U.S., South Korea exercises to resume

Aug. 17 (UPI) -- North Korea is keeping silent ahead of U.S.-South Korea military exercises this week.

World News // 23 hours ago

German regulators investigate Amazon pricing policies

Aug. 17 (UPI) -- Antitrust regulators in Germany are investigating complaints that Amazon is unfairly leveraging its dominant position in the e-commerce market to affect pricing during the coronavirus pandemic.

Excerpt from:
Israel and UAE team up on stem cell therapy research for COVID-19 - UPI News

Immatics Announces European Clinical Expansion of its Adoptive Cell Therapy Programs – GlobeNewswire

August 18, 2020 07:00 ET | Source: https://immatics.com/

multilang-release

Tuebingen, Germany and Houston, Texas, Aug. 18, 2020 (GLOBE NEWSWIRE) --

Tuebingen, Germany and Houston, Texas, August 18, 2020 Immatics N.V. (NASDAQ: IMTX, Immatics), a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting cancer immunotherapies, announced today the treatment of the first patient in the IMA202-101 trial in Europe following the Clinical Trial Application (CTA, the equivalent of an IND approval by FDA) approval by Paul-Ehrlich-Institute (PEI), the regulatory body for cell and gene therapies in Germany. In addition, Immatics has been granted regulatory approval by PEI to initiate another phase I clinical trial in Germany to evaluate safety, tolerability and initial signs of clinical efficacy of IMA203.

The clinical trials of the IMA200 series will investigate up to three novel cancer immunotherapies, which include IMA202 (NCT03441100) and IMA203 (NCT03686124). IMA202 and IMA203 are designed to target unique peptides derived from either melanoma-associated antigen 1 (MAGEA1) or preferentially expressed antigen in melanoma (PRAME), respectively. Both are built on Immatics proprietary ACTengine approach in which the patients own T cells are genetically engineered to express an exogenous T cell receptor (TCR) directed against true cancer targets. By introducing this novel cancer specific TCR, the goal is to redirect and selectively activate the patients T cells to fight the tumor. The studies will investigate the safety and tolerability of Immatics Adoptive Cell Therapies (ACT) in patients with target-positive solid cancers and seek initial signals of anti-tumor activity. Moreover, persistence of the infused engineered T cells will be monitored in the patients blood as T cell persistence is considered a major pre-requisite to obtain an anti-tumor response. The aim is to develop innovative personalized immunotherapies targeting a patients tumor selectively and effectively.

The initial group of clinical trial sites in Germany includes the University Hospital Carl Gustav Carus in Dresden, the University Hospital Bonn and the University Hospital of Wrzburg. Previous patients in the IMA200 series were initially enrolled at The University of Texas MD Anderson Cancer Center in Houston, Texas, and more recently at the Columbia University Irving Medical Center in New York and the UPMC Hillman Cancer Center in Pittsburgh, Pennsylvania.

Cedrik Britten, MD, Chief Medical Officer of Immatics commented: As part of our strategy to increase the geographical foot-print for our clinical sites, we are currently expanding them in the US and in Europe. We are delighted to have gained a new regulatory approval from PEI and to have treated the first patient in Germany. This expansion elevates our clinical organization to a global level and adds operational flexibility that has become even more important in light of the global COVID-19 pandemic. We look forward to continuing to collaborate with leading clinicians to advance our mission of delivering the power of T cells to cancer patients on both sides of the Atlantic.

Dr. Martin Wermke, Coordinating Investigator and Head of the Early Clinical Trial Unit of the National Center for Tumor Diseases Dresden (NCT/UCC) at the University Hospital Carl Gustav Carus in Dresden, Germany, commented: Having been involved since the early stages of this clinical research, I am excited to witness the next phase of development of this fascinating pipeline of immunotherapies. I am confident that Immatics innovative T cell therapies hold the potential to alter the future therapeutic landscape of solid and hematologic malignancies.

Additional information about the clinical studies is available at http://www.immatics.com/clinical-programs/ and http://www.clinicaltrials.gov.

About Immatics Adoptive Cell Therapies Adoptive Cell Therapy (ACT) is a therapeutic approach that uses natural or engineered T cells to fight cancer. Immatics has developed three innovative, proprietary approaches to produce Adoptive Cell Therapies: ACTengine, off-the-shelf ACTallo and the multi-target pilot trial ACTolog.

About ACTengine Immatics clinical product class ACTengine is a personalized approach for patients with advanced solid cancers. Patients own T cells are genetically modified to express a novel proprietary TCR cognate to one of Immatics cancer targets identified by its proprietary XPRESIDENT target discovery platform.

About the ACTengine clinical trials (IMA201, IMA202 and IMA203)

Patient receiving an investigational therapy based on Immatics ACTengine approach.

Notes to Editors

About Immatics Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation for our pipeline of Adoptive Cell Therapies and TCR Bispecifics as well as our partnerships with global leaders in the pharmaceutical industry. We are committed to delivering the power of T cells and to unlocking new avenues for patients in their fight against cancer.

Immatics pipeline consists of two distinct therapeutic modalities of Adoptive Cell Therapies and TCR Bispecifics. Adoptive Cell Therapy programs are developed in collaboration through Immatics US with The University of Texas MD Anderson Cancer Center and co-funded by the Cancer Prevention and Research Institute of Texas (CPRIT). The ACT T cell products are manufactured at the Evelyn H. Griffin Stem Cell Therapeutics Research Laboratory in collaboration with UTHealth.

For regular updates about Immatics, visit http://www.immatics.com. You can also follow us on Twitter and LinkedIn.

Forward-Looking Statements: Certain statements in this press release may be considered forward-looking statements. Forward-looking statements generally relate to future events or Immatics future financial or operating performance. For example, statements concerning the timing of product candidates and Immatics focus on partnerships to advance its strategy are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as may, should, expect, intend, will, estimate, anticipate, believe, predict, potential or continue, or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Immatics and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Factors that may cause actual results to differ materially from current expectations include, but are not limited to, various factors beyond management's control including general economic conditions and other risks, uncertainties and factors set forth in filings with the Securities and Exchange Commission (SEC). Nothing in this presentation should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Immatics undertakes no duty to update these forward-looking statements.

Follow this link:
Immatics Announces European Clinical Expansion of its Adoptive Cell Therapy Programs - GlobeNewswire

Canine Stem Cell Therapy Market to Witness Stunning Growth to Generate Massive Revenue During Forecast 2020 2026 | VETSTEM BIOPHARMA, Cell Therapy…

Canine Stem Cell Therapy Market research is an intelligence report with meticulous efforts undertaken to study the right and valuable information. The data which has been looked upon is done considering both, the existing top players and the upcoming competitors. Business strategies of the key players and the new entering market industries are studied in detail. Well explained SWOT analysis, revenue share and contact information are shared in this report analysis.

The global Canine Stem Cell Therapy Market size is expected to Expand at Significant CAGR of +4% during forecast period (2020-2026).

The non-invasive stem cell obtaining procedure, augmented possibility of accomplishing high quality cells, and lower price of therapy coupled with high success rate of positive outcomes have collectively made allogeneic stem cell therapy a preference for veterinary physicians. Moreover, allogeneic stem cell therapy is 100% safe, which further supports its demand on a global level.

Get Sample Copy (Including FULL TOC, Graphs and Tables) of this report @:

https://www.a2zmarketresearch.com/sample?reportId=21262

Note In order to provide more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19.

Top Key Vendors of this Market are:

VETSTEM BIOPHARMA, Cell Therapy Sciences, Regeneus, Aratana Therapeutics, Medivet Biologics, Okyanos

Various factors are responsible for the markets growth trajectory, which are studied at length in the report. In addition, the report lists down the restraints that are posing threat to the global Canine Stem Cell Therapy market. It also gauges the bargaining power of suppliers and buyers, threat from new entrants and product substitute, and the degree of competition prevailing in the market. The influence of the latest government guidelines is also analyzed in detail in the report. It studies the Canine Stem Cell Therapy markets trajectory between forecast periods.

The report provides insights on the following pointers:

Market Penetration:Comprehensive information on the product portfolios of the top players in the Canine Stem Cell Therapy market.

Product Development/Innovation:Detailed insights on the upcoming technologies, R&D activities, and product launches in the market.

Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments of the leading players in the market.

Market Development:Comprehensive information about emerging markets. This report analyzes the market for various segments across geographies.

Market Diversification:Exhaustive information about new products, untapped geographies, recent developments, and investments in the Canine Stem Cell Therapy market.

Get Up to 20% Discount on this Premium Report @:

https://www.a2zmarketresearch.com/discount?reportId=21262

The report summarized the high revenue that has been generated across locations like, North America, Japan, Europe, Asia, and India along with the facts and figures of Canine Stem Cell Therapy market. It focuses on the major points, which are necessary to make positive impacts on the market policies, international transactions, speculation, and supply demand in the global market.

Global Canine Stem Cell Therapy Market Segmentation:

Market Segmentation by Type:

Allogeneic Stem Cells Autologous Stem cells

Market Segmentation by Application:

Veterinary Hospitals Veterinary Clinics Veterinary Research Institutes

Table of Contents

Global Canine Stem Cell Therapy Market Research Report 2020 2026

Chapter 1 Canine Stem Cell Therapy Market Overview

Chapter 2 Global Economic Impact on Industry

Chapter 3 Global Market Competition by Manufacturers

Chapter 4 Global Production, Revenue (Value) by Region

Chapter 5 Global Supply (Production), Consumption, Export, Import by Regions

Chapter 6 Global Production, Revenue (Value), Price Trend by Type

Chapter 7 Global Market Analysis by Application

Chapter 8 Manufacturing Cost Analysis

Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10 Marketing Strategy Analysis, Distributors/Traders

Chapter 11 Market Effect Factors Analysis

Chapter 12 Global Canine Stem Cell Therapy Market Forecast

For more Information, Inquire @:

https://www.a2zmarketresearch.com/enquiry?reportId=21262

If you have any special requirements, please let us know and we will offer you the report as you want.

About A2Z Market Research:

The A2Z Market Research library provides syndication reports from market researchers around the world. Ready-to-buy syndication Market research studies will help you find the most relevant business intelligence.

Our Research Analyst Provides business insights and market research reports for large and small businesses.

The company helps clients build business policies and grow in that market area. A2Z Market Research is not only interested in industry reports dealing with telecommunications, healthcare, pharmaceuticals, financial services, energy, technology, real estate, logistics, F & B, media, etc. but also your company data, country profiles, trends, information and analysis on the sector of your interest.

Contact Us:

Roger Smith

1887 WHITNEY MESA DR HENDERSON, NV 89014

[emailprotected]

+1 775 237 4147

Original post:
Canine Stem Cell Therapy Market to Witness Stunning Growth to Generate Massive Revenue During Forecast 2020 2026 | VETSTEM BIOPHARMA, Cell Therapy...

NK Cell Therapy and Stem Cell Therapy Industry Market Structure Analysis for the Period 2026 – The News Brok

The report on NK Cell Therapy and Stem Cell Therapy Industry market added by Market Study Report, LLC, depicts the current & future growth trends of this business besides outlining details pertaining to the myriad geographies that are a part of the regional landscape of NK Cell Therapy and Stem Cell Therapy Industry market. The report further elucidates intricate details regarding the supply and demand analysis, market share, growth statistics and contributions by leading industry players of NK Cell Therapy and Stem Cell Therapy Industry market.

The research report on NK Cell Therapy and Stem Cell Therapy Industry market delivers an exhaustive analysis of this business space while offering significant information pertaining to the factors that are affecting the revenue generation as well as the industry growth. The document also comprises of a detailed assessment of the regional scope of the market alongside its regulatory outlook. Additionally, the report provides with a detailed SWOT analysis while elaborating market driving factors.

Request a sample Report of NK Cell Therapy and Stem Cell Therapy Industry Market at:https://www.marketstudyreport.com/request-a-sample/2707408?utm_source=newsbrok&utm_medium=RV

Additional information including limitations & challenges faced by new entrants and market players in tandem with their respective impact on the revenue generation of the companies is enumerated. The document scrutinizes the impact of COVID-19 pandemic on growth as well as future remuneration of the market.

From the regional perspective of NK Cell Therapy and Stem Cell Therapy Industry market:

Emphasizing on the competitive scenario of the NK Cell Therapy and Stem Cell Therapy Industry market:

Ask for Discount on NK Cell Therapy and Stem Cell Therapy Industry Market Report at:https://www.marketstudyreport.com/check-for-discount/2707408?utm_source=newsbrok&utm_medium=RV

Other details specified in the NK Cell Therapy and Stem Cell Therapy Industry market report:

Comprehensive assessment of all opportunities and risks in the NK Cell Therapy and Stem Cell Therapy Industry market.

This exclusive study addresses key questions for stakeholders in the NK Cell Therapy and Stem Cell Therapy Industry Market:

For More Details On this Report: https://www.marketstudyreport.com/reports/covid-19-outbreak-global-nk-cell-therapy-and-stem-cell-therapy-industry-market-report-development-trends-threats-opportunities-and-competitive-landscape-in-2020

Related Reports:

1. COVID-19 Outbreak-Global Phycoerythrin Industry Market Report-Development Trends, Threats, Opportunities and Competitive Landscape in 2020 Read More: https://www.marketstudyreport.com/reports/covid-19-outbreak-global-phycoerythrin-industry-market-report-development-trends-threats-opportunities-and-competitive-landscape-in-2020

2. COVID-19 Outbreak-Global Electronic Emergency Ventilator Industry Market Report-Development Trends, Threats, Opportunities and Competitive Landscape in 2020 Read More: https://www.marketstudyreport.com/reports/covid-19-outbreak-global-electronic-emergency-ventilator-industry-market-report-development-trends-threats-opportunities-and-competitive-landscape-in-2020

Contact Us: Corporate Sales, Market Study Report LLC Phone: 1-302-273-0910 Toll Free: 1-866-764-2150 Email: [emailprotected]

Continued here:
NK Cell Therapy and Stem Cell Therapy Industry Market Structure Analysis for the Period 2026 - The News Brok

Why Young and Female Patients Don’t Respond as Well to Cancer Immunotherapy – UC San Diego Health

Cancer immunotherapy empowering a patients own immune system to clear away tumors on its own holds great promise for some patients. But for other patients, immunotherapy just doesnt work.

Researchers at University of California San Diego School of Medicine have found evidence that helps explain why patients who are young and/or female have especially low response rates to some types of cancer immunotherapy.

Their findings suggest that since the typically robust immune systems of young and female patients are better at getting rid of tumor cells, the cells left behind are not as readily visible to the immune system to begin with, rendering some types of immunotherapy ineffective.

Due to a process known as immuno-editing, younger and female patients with cancer have cancer-causing genetic mutations that are least visible to the immune system according to a new Nature Communications study by Hannah Carter, PhD, and team at UC San Diego School of Medicine.

The study is published August 17, 2020, in Nature Communications.

Now that we know why some patients dont respond as well to immunotherapy, we can begin developing more informed approaches to treatment decisions for instance, developing predictive algorithms to determine a persons likely response before initiating immunotherapies that may have a high probability of not working or working poorly for them, said senior author Hannah Carter, PhD, associate professor of medicine at UC San Diego School of Medicine.

Cancerous or infected cells wave molecular flags that tell the immune system to clear them away before the problem gets out of control. The flag poles molecules of the Major Histocompatibility Complexes (MHC) are displayed at the surface of most cells in the body. MHCs hold up antigen flags bits of just about everything from inside the cells and display them to immune cell surveyors that are constantly checking for damaged or infected cells. Since tumor cells carry a lot of mutations, they show up frequently among these flags, allowing the immune system to detect and eliminate them.

But some tumor cells evade the immune system by also throwing up a stop sign molecule that keeps the immune system from recognizing the MHC flags. And heres where immune checkpoint inhibitors come in: This type of cancer immunotherapy uses antibodies to make the tumor cell once again visible to the patients immune system.

So why would a persons age or sex influence how well immune checkpoint inhibitors work?

Sex and age differences have long been observed when it comes to immune response. For example, females have twice the antibody response to flu vaccines and are far more susceptible to autoimmune diseases. Similarly, human immune systems tend to weaken as we age. But if females and younger people have stronger immune responses in most cases, you might expect cancer immunotherapy to work better for them, not worse.

To get to the bottom of this conundrum, Carters team looked at genomic information for nearly 10,000 patients with cancer available from the National Institutes of Healths The Cancer Genome Atlas, and another 342 patients with other tumor types available from the International Cancer Genome Consortium database and published studies. They found no age or sex-related differences in MHC function.

What they did find was that, compared to older and male patients with cancer, younger and female patients tend to accumulate more cancer-causing genetic mutations of the sort that MHCs cant present to the immune system as efficiently. Carter said this is likely because robust immune systems of the young and female are better at getting rid of cells displaying well-presented mutant self-antigens, leaving behind tumor cells that rely more heavily on the poorly presented mutations. This selective pressure is known as immuno-editing.

So if a tumor cell doesnt present highly visible, mutated self antigens to begin with, checkpoint inhibitor drugs cant help reveal them to the immune system, she said.

This shows an important thing, that the interplay between the cancer genome and the adaptive arm of the immune system is not a static one, said co-author Maurizio Zanetti, MD, professor of medicine at UC San Diego School of Medicine and head of the Laboratory of Immunology at UC San Diego Moores Cancer Center. Two simple but important variables, age and sex, influence this interplay. The study also emphasizes the master role of the MHC in dictating the outcome of this interplay, reaffirming its central role in the evolution of disease, cancer included, at the level of the individual and population.

Carter cautions that their findings for younger patients dont necessarily apply to children since, genetically speaking, pediatric tumors are very different from adult tumors. In addition, she noted that, like most genomics databases, those used in this study contain data primarily from people of Caucasian descent, and more diversity is needed to confirm that the findings can be generalized to all populations.

Cancer isnt just one disease, and so the way we treat it cant be one-size-fits-all, she said. All checkpoint inhibitors can do is remove the generic block that tumors put up to hide from the immune system. The more we learn about how interactions between tumors and immune systems might vary, the better positioned we are to tailor treatments to each persons situation.

Co-authors of the study also include: Andrea Castro, Rachel Marty Pyke, Xinlian Zhang, Wesley Kurt Thompson, Ludmil B. Alexandrov, Maurizio Zanetti, UC San Diego; and Chi-Ping Day, National Institutes of Health.

The study was funded, in part, by the National Institutes of Health (grants T15LM011271, DP5-OD017937, RO1CA220009, P41GM103504, 5R01CA155010-02, 5R01HL103532-03, 2P50CA101942-11A1, R50RCA211482A, R35CA197633, P01CA168585, 5P50CA168536, GM08042, 1RO1CA155010-02, 5R01HL103532-03, R21CA216772-01A1, T32HL007627, P50CA165962, P01CA163205, K08CA188615), National Science Foundation (graduate fellowship 2015205295), Mark Foundation for Cancer Research (grant 18-022-ELA), CIFAR Fellowship, Blavatnik Family Foundation, Broad Institute SPARC Program, BroadIgnite, BroadNext10, Francis and Adele Kittredge Family Immuno-Oncology and Melanoma Research Fund, Faircloth Family Research Fund, DFCI Center for Cancer Immunotherapy, Leukemia and Lymphoma Society, American Association for Cancer Research, Geoffrey Beene Cancer Research Center, Society for Memorial Sloan Kettering Cancer Center, Lung Cancer Research Foundation, Frederick Adler Chair Fund, One Ball Matt Memorial Golf Tournament, Queen Wilhelmina Cancer Research Award, STARR Foundation, Ludwig Trust, Stand Up To Cancer-Cancer Research Institute Cancer Immunology Translational Cancer Research Grant, Stand Up To Cancer-American Cancer Society Lung Cancer Dream Team Translational Research Grant (grant SU2C-AACR-DT17-15), Ben and Catherine Ivy Foundation, Zuckerman STEM Leadership Program, Benoziyo Endowment Fund for the Advancement of Science, DFCI Center for Cancer Immunotherapy Research fellowship, Howard Hughes Medical Institute and American Cancer Society (grant PF-17-042-01LIB).

Disclosure: Co-author Rachel Marty Pyke is an employee and holds stock in Personalis.

View original post here:
Why Young and Female Patients Don't Respond as Well to Cancer Immunotherapy - UC San Diego Health